Navigation Links
LSTM-Eisai-UoL awarded GHIT Fund to deliver anti-Wolbachia drug discovery
Date:3/20/2014

The Liverpool School of Tropical Medicine (LSTM) together with colleagues at the Department of Chemistry (University of Liverpool (UoL)) and Japanese pharmaceutical company Eisai are pleased to announce that they have been award a Global Health Innovative Technology (GHIT) Fund to develop new drugs to target lymphatic filariasis and onchocerciasis. The GHIT Fund facilitates and funds global partnerships for the discovery and development of new health technologies, including drugs, vaccines and diagnostics, for infectious and neglected tropical diseases prevalent in developing countries.

Researchers will aim to identify and develop new drug candidates that efficiently kill the intracellular bacteria Wolbachia living inside the parasitic worms responsible for both lymphatic filariasis (elephantiasis) and onchocerciasis (river blindness) - debilitating infections affecting more than 150 million people globally.

LSTM, through the AWOL Consortium has already shown that a 4-6 week course of the antibiotic doxycycline can deplete Wolbachia from the parasitic worms, leading to worm sterility and slow worm death, thereby breaking the parasitic life-cycle and limiting adverse host immune response. This unique anti-Wolbachia treatment has already been adopted by international health programmes as it has many benefits, including potential for deployment in regions co-endemic with Loa loa and the ability to reduced treatment timeframes compared to standard anti-filarial drugs. However, the use of doxycycline remains limited due to it unsuitability for use in pregnant women and children. To combat these issues, the AWOL Consortium is developing new drugs and discovering new drug candidates that can be used in all populations and with reduced treatment times as short as 7 days. This success was achieved by screening over 60,000 compounds to test their ability to kill Wolbachia. With the GHIT award, the most promising drug candidates will proceed through advanced rounds of chemical modification and testing to identify lead candidate compounds that have a good safety and efficacy profiles ready to move into pre-clinical testing.

With tropical disease expertise led by Prof Steve Ward and Prof Mark Taylor based at LSTM, chemical optimisation of analogues will be performed at Eisai in collaboration with Prof Paul O'Neill's laboratory at the Department of Chemistry, UoL. This unique partnership brings together internationally recognised drug discovery expertise focusing on a novel approach to address the current challenges of two parasitic diseases that affect the lives of many millions of people globally.


'/>"/>

Contact: Clare Bebb
c.bebb@liv.ac.uk
44-015-170-53135
Liverpool School of Tropical Medicine
Source:Eurekalert

Related medicine news :

1. Kessler Foundation MS scientist awarded Patterson Trust Award in Clinical Research
2. Sloan Research Fellowships awarded to 126 young scholars
3. Director of Womens Guild Lung Institute awarded grant to study treatment for lung disease
4. UC Irvine stem cell researchers awarded $1.54 million in state funding
5. IU School of Medicine researchers awarded $300,000 GE/NFL grant to study concussions
6. UTSA/UTHSCSA awarded $900,000 to prevent substance abuse and HIV/AIDS transmission
7. Mass. Eye and Ear physician awarded RPB Career Development Award
8. Researchers awarded grant from the DeGregorio Family Foundation
9. Obesity Solutions Mexico Directed by Dr. Jose A. Castaneda Awarded 2013's Best Bariatric Surgeon by allPrivateHealth.com
10. Family Voices Awarded Project to Fight Childhood Obesity by the Patient-Centered Outcomes Research Institute
11. Population Council awarded USAID cooperative agreement to develop non-antiretroviral HIV microbicide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Silver Spring, MD (PRWEB) , ... January 18, 2017 , ... ... and financial consultations to families and business owners in central Maryland and the DC ... community. , Heart disease kills 787,000 people nationally every year, making it the #1 ...
(Date:1/18/2017)... N.J. (PRWEB) , ... January 18, 2017 , ... ... delivery technologies and development solutions for drugs, biologics and consumer health products, today ... will be presenting at the upcoming WCBP Conference, to be held at the ...
(Date:1/18/2017)... Hills, CA (PRWEB) , ... January 18, 2017 ... ... of dental problems ranging from gum disease to enamel erosion, and those dental ... the Massachusetts Department of Public Health, many pregnant women are failing to get ...
(Date:1/17/2017)... ... January 17, 2017 , ... Gym Source, America’s leading retailer of ... at South Dixie Hwy in Miami, FL. , “We are elated to be opening ... innovative in-store concept is designed to give clients a seamless and motivating shopping experience.” ...
(Date:1/17/2017)... Phoenix, AZ (PRWEB) , ... January 17, 2017 ... ... new and improved supplement, Healthful-Flex. , The company, owned and operated by ... the public at a reasonable price with the highest level of customer service. ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... After the recent election cycle, it is clear ... for medical and recreational purposes are shifting. The evidence shows ... of cannabis, but the focus is coming from both the ... North American legal cannabis market posted $6.7 billion in revenue ... projects sales will grow at a compound annual growth rate ...
(Date:1/17/2017)... , Jan. 17, 2017 Precision medicine ... for the treatment of disease. The approach allows ... to a therapy. The approach studies the individual ... lifestyle and environment. In January 2015, Precision Medicine ... to all diseases with more than one million ...
(Date:1/17/2017)... , Jan. 17, 2017 EU5 Glucose Monitoring ... new report, "EU5 Glucose Monitoring Market Outlook to 2022", ... market. The report provides value, in millions of US ... market segments - Blood Glucose Meters, Blood Glucose Test ... shares and distribution shares data for each of these ...
Breaking Medicine Technology: